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doi:10.1016/j.jmii.2011.01.014Malaria is endemic in Malaysia. Leishmaniasis is a protozoan infection rarely reported in
Malaysia. Here, a 24-year-old Nepalese man who presented with prolonged fever and he-
patosplenomegaly is reported. Blood film examination confirmed a Plasmodium vivax ma-
laria infection. Despite being adequately treated for malaria, his fever persisted. Bone
marrow examination showed presence of Leishman-Donovan complex. He was success-
fully treated with prolonged course of amphotericin B. The case highlights the impor-
tance of awareness among the treating physicians of this disease occurring in a foreign
national from an endemic region when he presents with fever and hepatosplenomegaly.
Coinfection with malaria can occur although it is rare. It can cause significant delay of the
diagnosis of leishmaniasis.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Malaysia is a tropical country and located in the region of
Southeast Asia. Malaria is endemic in this region, whereasisease Clinic, Department of
ah, Kuala Terengganu, 20400
oo.com (A.K. Ab Rahman).
an Society of Microbiology. Publleishmaniasis is not. Malaysia is considered free of endemic
Leishmania species although few species of Malaysian
sandflies have been described, possibly because the sand-
flies are not largely anthropophilic.1,3 However, with the
advancement of world travel today, including migration of
refugees or workers from endemic regions, visceral leish-
maniasis (VL) has emerged as an increasingly important and
imported infection in many countries. Cases of cutaneous
leishmaniasis have doubled and tripled in the Netherlandsished by Elsevier Taiwan LLC. All rights reserved.
Visceral leishmaniasis and malaria coinfection 73and the United Kingdom, respectively, in the past decade,
whereas cutaneous leishmaniasis and VL cases in Australia
have increased in significant numbers over the past few
years.2 Therefore, this condition needs to be suspected in
someone who presents with prolonged fever and has history
of recent travel or among the immigrants originated from
endemic area.
Here, we report a case of a foreign worker who had been
referred to us from a district hospital for the management
of prolonged fever after successful treatment of malaria
infection.
Case report
The patient was a 24-year-old apparently healthy gentleman
from Nepal, arrived in Malaysia in August 2007 after being
successfully secured an employment as a construction
worker in one of the states in Malaysia. His problem started 2
weeks after his arrival, with insidious onset, on and off
moderate grade of fever. Subsequently, he developed vague
abdominal pain, which was mild and intermittent in nature.
He stayed in an overcrowded temporary hostel with other
new immigrant workers from various countries of origin. He
ate the same food with others. He denied any history of
vomiting or diarrhea.
At the second week of illness, his condition got worse,
with more persistent fever. The left-sided abdominal pain
persisted and became more intense and unbearable. At
this point, he decided to seek for medical treatment. He
admitted himself at one of the district hospital in the state
of Terengganu, one of the 14 states in Malaysia. Septic
workup, including blood culture, blood film for malaria
parasite, urine culture, typhus serology, and typhoid
serology was carried out.
The blood film result was positive for Plasmodium vivax
with a parasite density of 8,000/mL (Fig. 1). Oral chloro-
quine (600 mg) was given initially as a loading dose, fol-
lowed by another 300 mg 6 hours later and subsequently
300 mg daily for 2 more days. Oral primaquine (15 mg daily)
was then added on (after reviewing his glucose-6-phos-
phate dehydrogenase profile). Oral primaquine was given
for a total of 14 days.Figure 1. Blood film smear of the patient showing the
presence of Plasmodium vivax trophozoite.After 7 days of adequate antimalarial therapy, he still
has persistent spikes of temperature and did not look well.
His appetite remained poor. Posttreatment blood films for
malaria parasite were negative for plasmodium parasite.
He was referred to Hospital Sultanah Nur Zahirah (HSNZ)
during the second week of treatment. HSNZ is located in
Kuala Terengganu, the capital city of Terengganu. HSNZ
serves as a referral and secondary hospital for the state of
Terengganu.
At presentation to HSNZ, he looked lethargic but not ill.
His vital signs were in the normal range. His body temper-
ature was 38.3C. He appeared pale but not jaundiced. His
skin looked normal. The spleen was visibly enlarged,
crossing the umbilical line, and firm but nontender. He was
also noted to have enlarged liver, approximately 6 cm
below the right subcostal margin (Fig. 2).
Ultrasonic study of the abdomen and pelvis was normal.
A 2D echocardiography was carried out to look for evidence
of bacterial endocarditis, which was later found to be
normal. He had another cycle of septic workup mentioned
above, and the results were all negative.
Because of worsening pancytopenia (Table 1), he
underwent a diagnostic bone marrow aspiration procedure,
and the result of marrow aspirate is shown in Fig. 3A and B.
With the above findings, daily intravenous infusion of
amphotericin B deoxycholate was started. He became
afebrile on Day 5 of the treatment and remained well until
the day he was discharged home. He received a total
cumulative dose of 1.26 g or 21 mg/kg of amphotericin B.
His renal function was monitored at biweekly interval.
Serum creatinine and serum potassium were normal
throughout the course of treatment with amphotericin B.
Serial follow-up of full blood counts during the course of
treatment showed spontaneous recovery of all the three
cell lines (Table 2). Six months after discharge, he was seen
again at the clinic. He was otherwise well and asymptom-
atic. No repeat bone marrow examination was carried out.
Discussion
Differential diagnoses in patient with massive hepatos-
plenomegaly, fever, and pancytopenia are not many.Figure 2. Photograph of the patient’s abdomen with massive
hepatosplenomegaly.
Table 1 Series of full blood count results showing worsening leucopenia, anemia, and thrombocytopenia during malaria
treatment in Hospital Sultanah Nur Zahirah
Nov 18, 2007
(Day 1)
Nov 25, 2007
(Day 8)
Dec 03, 2007
(Day 15)
Dec 09, 2007
(Posttreatment completion)
TWC (109/L) 1.6 1.5 0.9 1.0
Hb (g/dL) 7.7 7.9 6.6 6.8
Platelet (cells/mm3) 141,000 134,000 69,000 63,000
HbZ hemoglobin; TWCZ total white blood cell count.
74 A.K. Ab Rahman, F.H. AbdullahChronic myeloid leukemia, myelofibrosis, non-Hodgkin
lymphoma, and Gaucher disease are some of the recognized
noninfectious causes of these conditions. Infectious causes
of massive splenomegaly in tropical countries and malarial
endemic area are chronic malaria and tropical spleno-
megaly. Little information exists on the true incidence of
leishmaniasis in Malaysia, especially among the immigrants
coming from the endemic region, because it is not a notifi-
able disease in this country. Physicians generally are not
aware of this disease, and the lack of experience andFigure 3. (A) Marrow aspirate of the patient showing
numerous extracellular amastigotes (thick arrow). (B) Intra-
macrophage amastigotes of Leishmania (Leishman-Donovan
bodies) (thin arrow).knowledge in managing this illness may lead to unnecessary
delay in the treatment initiation. To our knowledge, this is
the second case of VL reported in Malaysia. The first case of
VL in Malaysia was reported in a young immigrant suspected
to have hematological malignancy in 1995.4
The Leishmania donovani complex includes Leishmania
chagasi and Leishmania infantum and causes VL, a dissem-
inated and potentially fatal form of leishmaniasis. It is
transmitted by indigenous sandflies, which is the only
vector responsible for the transmission of the parasite.
Leishmaniasis is considered to be endemic in many coun-
tries, including India, Nepal, and Bangladesh. India alone
may contribute as many as 40% to 50% of the world’s cases.5
The confirmatory diagnosis of leishmaniasis relies on
either the microscopical demonstration of Leishmania
amastigotes in the relevant tissue aspirates or the biopsies,
such as bone marrow, spleen, lymph nodes or liver, slit skin
smears or biopsies, or in the peripheral blood buffy coat.
Splenic aspiration appears to be more sensitive than
bone marrow aspirate with Leishman-Donovan bodies found
in 90% and 76% to 85%, respectively.6,7 However, the safety
of splenic aspiration procedure is operator dependant. It is
not widely used as a diagnostic procedure in this country.
Bone marrow aspiration is widely practiced here for the
diagnosis of other disease conditions. It is considered as
a more acceptable mode of diagnosis, less hazardous with
no major complications, although it has a sensitivity of
about 50% to 60%.7
Apart for diagnostic purposes, bone marrow biopsy
findings can also be helpful for assessing the prognosis of VL
patients, in terms of recovery of affected marrow cells. The
outcome of treatment seems to be excellent in cases of
hypercellular marrow. The presence of extensive fibrosis
and necrosis of the marrow associated with very poor
outcome, whereas granuloma if present is usually resulted
in moderate response.8 In the above-mentioned case, the
marrow architecture was hypercellular, without the pres-
ence of significant necrosis or granuloma. We expected that
he will have a good chance of total recovery with regard to
the marrow profiles.
The direct agglutination test (DAT) is a highly specific and
sensitive test. It is cheap and simple to perform, making it
ideal for both field and laboratory use. DAT in various studies
has been found to be 91% to 100% sensitive and 72% to 100%
specific.7 For long time, DAT remained first-line diagnostic
tool in resource poor countries. However, polymerase chain
reaction has been proven to be the most specific and
sensitive technique (100% and 80e93.3%, respectively),
albeit limited to tertiary care hospitals and research
laboratories.7
Table 2 Series of full blood count results showing recovery of leucopenia, anemia, and thrombocytopenia during treatment
with amphotericin B
Dec 17, 2007
(Day 8)
Dec 24, 2007
(Day 15)
Dec 31, 2007
(Day 21)
Jan 16, 2008
(Posttreatment completion)
TWC (109/L) 3.8 2.5 4.1 4.6
Hb (g/dL) 6.4 8.4 9.6 9.5
Platelet (cells/mm3) 105,000 153,000 125,000 253,000
HbZ hemoglobin; TWCZ total white blood cell count.
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and meglumine antimoniate remains the first-line treat-
ment in all regions of the developing world because of
decades of clinical experience. It has proven efficacy with
greater than 90% of long-term cure rate with acceptable
cost.
The development of resistance to first-line therapy
necessitated the use of even more expensive and more
toxic second-line drugs like amphotericin B.9 Data from the
immunocompetent European VL patients demonstrated
that 100% cure rate was achieved if treated with a total
dose of greater than 21 mg/kg of amphotericin B.10 More
commonly now, at least in India, infusions of 1 mg/kg given
either daily for 20 days or on alternate days (15 infusions
over 30 days) for a total dose of 15 mg/kg are used,
resulting in uniformly high efficacy with long-term cure rate
of greater than or equal to 96%.11,12 A more recent study by
Sundar et al.12 in 2007 found that amphotericin B can be
effectively and safely given at a lower dose, that is,
0.75 mg/kg daily for 15 days (total dose, 11.25 mg/kg) with
comparable cure rates (96%) and shorter duration of
hospital stay.
Results from another study in India demonstrated that
lipid formulation amphotericin, that is, AmBisome and
Abelcet produced an overall cure rates similar to conven-
tional amphotericin B (amphotericin B >96%, AmBisome
>96%, and Abelcet >92%), with fewer infusion-related
reactions and little toxicity.13 However, the cost of these
drugs is expensive, thus limiting its potential use in the
treatment of leishmaniasis in many countries.
For the case under discussion, conventional amphoter-
icin B was chosen because it is more readily available and
comparatively much cheaper than the lipid formulation
amphotericin. Pentavalent antimony is not available here.
Lipid formulation amphotericin is expensive and not readily
available in most government hospitals in Malaysia. He
completed a total cumulative dose of 21mg/kg of intra-
venous infusion of amphotericin B. Close monitoring of the
renal function and serum electrolyte as well as ensuring
good hydration status were carried out during the treat-
ment period, hence minimizing the risk of amphotericin-
related toxicity.
VL with chronic malaria in undernourished children was
known as malarial cachexia in Imperial India, although
presently, concomitant infection is rarely reported. Only
few human cases of concomitant malaria and leishmaniasis
have been reported.14,15 In previously reported case of
malaria coinfection, marked pancytopenia with severe
neutropenia was noted,14 as what had happened to our
patient. However, the abnormalities were self-limited and
improved dramatically with the initiation of therapy.Chronic VL is known to cause CD4 lymphopenia and
a low CD4:CD8 ratio, whereas blood CD4:CD8 ratio
remains unaltered during malarial paroxysms. The study
by Rohatgi et al.16 in leishmaniasis patients found that the
pretreatment CD4 cell count was depressed in the
peripheral blood of acute and chronic VL cases but higher
in the bone marrow. An influx of CD4 cells to the bone
marrow and spleen might account for the fall in the
CD4:CD8 cell ratio in the blood observed.16 Studies using
experimental models of malaria in immune-deficient mice
and chickens have shown that resistance to blood-stage
infection is mediated by protective antibodies and T cell-
dependent cell-mediated mechanisms of immunity.17
Therefore, it seems that leishmaniasis-mediated CD4
lymphopenia may have nullified the protective effect
against malaria.14
Leishmaniasis is not endemic in this region. However, it
is becoming important to recognize this disease, espe-
cially among the migrants from endemic regions or those
who had recently traveled to those countries. Because of
the issue of safety and familiarity with the procedure,
bone marrow examination remained the preferred method
of parasite identification. The treatment of VL is prolong
and expensive. In many countries, including Malaysia,
conventional amphotericin B still has a role in the treat-
ment of VL. With close and regular monitoring of renal
function and ensuring good hydration status of the
patient, its toxicity effect can be minimized. Coinfection
with malaria is rare, but it may have significant impact on
the delay of diagnosis. A high clinical suspicion is neces-
sary among the primary care practitioners about the
threat of imported infectious disease, especially among
the patients who presented with prolonged febrile illness
and hepatosplenomegaly.Acknowledgment
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